Cited by 1,226Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAging, Health, and Disability

The DOI matches its Crossref record.

Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported

Evans, Denis A.·1989·JAMA

DOI 10.1001/jama.1989.03430180093036

Open this paper in CoChat — free account

Abstract

Clinically diagnosed Alzheimer's disease and other dementing illnesses were assessed in a geographically defined US community. Of 3623 persons (80.8% of all community residents over 65 years of age) who had brief memory testing in their homes, a stratified sample of 467 persons underwent neurological, neuropsychological, and laboratory examination. Prevalence rates of Alzheimer's disease were calculated for the community population from the sample undergoing clinical evaluation. Of those over the age of 65 years, an estimated 10.3% (95% confidence limits, 8.1% and 12.5%) had probable Alzheimer's disease. This prevalence rate was strongly associated with age. Of those 65 to 74 years old, 3.0% (95% confidence limits, 0.8 and 5.2) had probable Alzheimer's disease, compared with 18.7% (95% confidence limits, 13.2 and 24.2) of those 75 to 84 years old and 47.2% (95% confidence limits, 37.0 and 63.2) of those over 85 years. Other dementing conditions were uncommon. Of community residents with moderate or severe cognitive impairment, 84.1% had clinically diagnosed Alzheimer's disease as the only probable diagnosis. These data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population. (JAMA. 1989;262:2551-2556)

Integrity signals

Registry

Crossref · 10.1001/jama.1989.03430180093036

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 401–500 of 1,000

The Effects of Long-Term Treatment with Metrifonate, a Cholinesterase Inhibitor, on Cholinergic Activity, Amyloid Pathology, and Cognitive Function in APP and PS1 Doubly Transgenic Mice
Liu, L., Ikonen, S., Heikkinen, T., Tapiola, T., Groen, T. V., & Tanila, H. (2002) · Experimental Neurology · doi:10.1006/exnr.2001.7819 · Cited by 51
Cognitive Assessment and Differentiating the 3 Ds (Dementia, Depression, Delirium)
Milisen, K., Braes, T., Fick, D. M., & Foreman, M. D. (2006) · Nursing Clinics of North America · doi:10.1016/j.cnur.2005.09.001 · Cited by 51
ApoE genotype in relation to AD and cholesterol
Liu, H. C., Hong, C. J., Wang, S. J., Fuh, J., WANG, P., Shyu, H.-Y., & Teng, E. L. (1999) · Neurology · doi:10.1212/wnl.53.5.962 · Cited by 53
Donepezil in Alzheimer’s disease: an evidence-based review of its impact on clinical and economic outcomes
Journal, C. (2006) · Core evidence · doi:10.2147/ce.s7447 · Cited by 53
“This trend is likely to be repeated in many other countries where numbers of people aged over 65 years are expected to increase and accompanied by disproportionate increases in dementia.”
The role of information in successful aging: The case for a research focus on the oldest old
Asla, T., Williamson, K., & Mills, J. (2006) · Library & Information Science Research · doi:10.1016/j.lisr.2005.11.005 · Cited by 53
Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice
Deipolyi, A. R., Fang, S., Palop, J. J., Yu, G.-Q., Wang, X., & Mucke, L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.021 · Cited by 52
The Effects of Church Attendance and Marital Status on the Longitudinal Trajectories of Depressed Mood Among Older Adults
Law, R. W., & Sbarra, D. A. (2009) · Journal of Aging and Health · doi:10.1177/0898264309338300 · Cited by 52
“For instance, dementia is a common condition among the elderly population that affects approximately 3% of those aged 65 to 74, 19% of those aged 75 to 84, and 47% of those aged 85 years or above (Evans et al., 1989).”
Background
Assessment of Suspected Dementia
Chertkow, H. M., Bergman, H., Schipper, H. M., Clarfield, A. M., Gauthier, S. G., Fontaine, S., & Bouchard, R. W. (2001) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100001189 · Cited by 52
Early Detection of Alzheimer's Disease by Combining Apolipoprotein E and Neuroimaginga
Small, G. W., Komo, S., Rue, A. L., Saxena, S., Phelps, M. E., Mazziotta, J. C., Saunders, A. M., Haines, J. L., Pericak‐Vance, M. A., & Roses, A. D. (1996) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1996.tb32600.x · Cited by 52
Hippocampal excitatory amino acid receptors in elderly, normal individuals and those with Alzheimer's disease: Non-N-methyl-d-aspartate receptors
Geddes, J. W., Ułas, J., Brunner, L. C., Choe, W. S., & Cotman, C. W. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90379-g · Cited by 52
Bilateral intracerebroventricular injection of streptozotocin induces AD-like behavioral impairments and neuropathological features in mice: Involved with the fundamental role of neuroinflammation
Fan, M., Liu, S., Sun, H.-M., Ma, M.-D., Gao, Y.-J., Qi, C.-C., Xia, Q.-R., & Ge, J.-F. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113375 · Cited by 50
Toward the processing speed theory of activities of daily living in healthy aging: normative data of the Functional Activities Questionnaire
Bezdíček, O., Štěpánková, H., Nováková, L. M., & Kopeček, M. (2015) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0413-5 · Cited by 51
“In Table 5, we present percentile values for three different age groups [38, 39] from 60 to 96 years of age to show the prominent influence of age on IADLs in a healthy aging population.”
BackgroundMethod
Caregiving appraisal and interventions based on the progressively lowered stress threshold model
Stolley, J. M., Reed, D., & Buckwalter, K. C. (2002) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750201700211 · Cited by 50
Update on Frontotemporal Dementia
Arvanitakis, Z. (2010) · The Neurologist · doi:10.1097/nrl.0b013e3181b1d5c6 · Cited by 55
“Studies suggest that the prevalence of dementia is about 5% in persons older than 65 years of age, and up to 50% in persons older than 85 years.(2) The clinician’s ability to recognize different causes of dementia and to make a specific diagnosis is improving with advances in medical research and technology.”
Background
Noggin and BMP4 co-modulate adult hippocampal neurogenesis in the APPswe/PS1ΔE9 transgenic mouse model of Alzheimer’s disease
Tang, J., Song, M., Wang, Y., Fan, X., Xu, H., & Bai, Y. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.05.067 · Cited by 50
Plants traditionally used in age-related brain disorders (dementia): an ethanopharmacological survey
Suganthy, N., Pandian, S. K., & Kasi, P. D. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2012.738423 · Cited by 53
“Dementia is alarmingly prevalent in the elderly population, affecting 5% of people over the age of 65 and up to 50% of people over the age of 85 (Evans et al., 1989).”
Background
Le test des 5 mots : validité dans la détection de la maladie d’Alzheimer dans la population générale
Cowppli-Bony, P., Fabrigoule, C., Letenneur, L., Ritchie, K. A., Alpérovitch, A., Dartigues, J., & Dubois, B. (2005) · Revue Neurologique · doi:10.1016/s0035-3787(05)85194-x · Cited by 49
“La méconnaissance de la MA se retrouve aux États-Unis (Evans et al. , 1989) et en Angleterre où on estime que seuls 58 p. 100 des praticiens de ville pratiquent un dépistage et que moins d’un quart des démences légères sont repérées (O’Connor et al. , 1988).”
Pupillary Response to Tropicamide in Patients with Alzheimer Disease
Loupe, D. N., Newman, N. J., Green, R. C., Lynn, M., Williams, K. K., Geis, T. C., & Edelhauser, H. F. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30666-0 · Cited by 51
Amyloid-beta and tau proteins as biochemical markers of Alzheimer's disease
Sobów, T., Flirski, M., & Liberski, P. P. (2004) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2004-1491 · Cited by 53
“…words: amyloid-beta, tau, Alzheimer’s disease, biomarkers R ev INTRODUCTION The prevalence of AD in the population of developed countries has been estimated at 5-11% of those aged 65 years or over, rising to as much as 50% among those aged over 85 years (Evans et al. 1989).”
Background
Age-Associated Memory Loss: Initial Neuropsychological and Cerebral Metabolic Findings of a Longitudinal Study
Small, G. W., Okonek, A., Mandelkern, M. A., Rue, A. L., Chang, L., Khonsary, A., Ropchan, J., & Blahd, W. H. (1994) · International Psychogeriatrics · doi:10.1017/s1041610294001596 · Cited by 50
Validity of the Mattis Dementia Rating Scale for detection of cognitive impairment in the elderly
Green, R. C., Woodard, J. L., & Green, J. (1995) · Journal of Neuropsychiatry · doi:10.1176/jnp.7.3.357 · Cited by 51
A Regulatory Role for the Insulin- and BDNF-Linked RORA in the Hippocampus: Implications for Alzheimer's Disease
Acquaah-Mensah, G. K., Agu, N., Khan, T., & Gardner, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141731 · Cited by 49
“Alzheimer’s disease (AD) is a leading cause of dementia in the aging population [1].”
Background
Are cognitively impaired individuals adequately represented in community surveys? Recruitment challenges and strategies to facilitate participation in community surveys of older adults. A review
Riedel-Heller, S. G., Busse, A., & Angermeyer, M. C. (2000) · European Journal of Epidemiology · doi:10.1023/a:1007615119222 · Cited by 50
L‐Deprenyl in the Treatment of Mild Dementia of the Alzheimer Type: Results of a 15–Month Trial
Burke, W. J., Roccaforte, W. H., Wengel, S. P., Bayer, B. L., Ranno, A. E., & Willcockson, N. K. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb07306.x · Cited by 50
Behavioral profile of possible Alzheimer's disease patients in Virginia search and rescue incidents
Koester, R. J., & Stooksbury, D. E. (1995) · Wilderness and Environmental Medicine · doi:10.1016/s1080-6032(13)80007-5 · Cited by 49
Dementia in Down’s syndrome: an MRI comparison with Alzheimer’s disease in the general population
Mullins, D., Daly, E., Simmons, A., Beacher, F. D. C. C., Foy, C. M. L., Lovestone, S., Hallahan, B. P., Murphy, K. C., & Murphy, D. (2013) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-5-19 · Cited by 50
“In the general population, approximately 10% of 65-yearolds and 40% of 80-year-olds, develop symptoms of AD [1].”
A comparative study to screen dementia and APOE genotypes in an ageing East African population
Chen, C.-H., Mizuno, T., Elston, R. C., Kariuki, M. M., Hall, K. S., Unverzagt, F., Hendrie, H. C., Gatere, S., Kioy, P. G., Patel, N. B., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.014 · Cited by 48
“Alzheimer’s disease (AD), as one of the main causes of dementia, is also expected to rise in the developing countries given the increasing demographic transition (Evans et al., 1989; Ferri et al., 2005) and prevalence of vascular disease (Kalaria, 2000, 2003).”
Genetic studies in Alzheimer's disease
Tang, Y., & Gershon, E. S. (2003) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2003.5.1/yptang · Cited by 52
“However, it was only in the 1960s that came to be recognized as the most common cause of dementia in the aged.(2) AD currently accounts for at least 60% to 70% of cases of dementia in aged people.”
BackgroundInfluential
Dietary Polyphenol Supplementation Prevents Alterations of Spatial Navigation in Middle-Aged Mice
Bensalem, J., Servant, L., Alfos, S., Gaudout, D., Layé, S., Lafenêtre, P., & Pallet, V. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00009 · Cited by 54
Is there a neuropathology difference between mild cognitive impairment and dementia?
Haroutunian, V. H., Hoffman, L. B., & Been, M. S. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/vharoutunian · Cited by 52
Validity and reliability of the Dysfunctional Behaviour Rating Instrument
Molloy, D. W., Mcllroy, W. E., Guyatt, G. H., & Lever, J. A. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb01429.x · Cited by 49
Dental management of patients with Alzheimer's disease and other dementias
Ettinger, R. L. (2000) · Gerodontology · doi:10.1111/j.1741-2358.2000.00008.x · Cited by 49
Measuring Functional Competence in Older Persons With Alzheimer’s Disease
Doble, S. E., Fisk, J. D., MacPherson, K. M., et al. (1997) · International Psychogeriatrics · doi:10.1017/s1041610297004171 · Cited by 48
Diagnostic challenges in dementia
Kaye, J. A. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s45 · Cited by 50
Emerging role of antioxidants in Alzheimer's disease: Insight into physiological, pathological mechanisms and management
Kamaljeet, Singh, S., Gupta, G. D., & Aran, K. R. (2023) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2023.100021 · Cited by 52
“It primarily affects individuals over 65 years of age and in ﬂ uences various cognitive functions, including language, memory, understanding, attention, judgment, and reasoning [2].”
Familial idiopathic normal pressure hydrocephalus
Huovinen, J., Kastinen, S., Komulainen, S., Oinas, M., Avellan, C., Frantzén, J., Rinne, J., Ronkainen, A., Kauppinen, M. T., Lönnrot, K., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.06.052 · Cited by 50
A novel selective androgen receptor modulator, NEP28, is efficacious in muscle and brain without serious side effects on prostate
Akita, K., Harada, K., Ichihara, J., Takata, N., Takahashi, Y., & Saito, K. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.042 · Cited by 47
“Age-related androgen depletion is considered as the most significant risk factor for the development of Alzheimer's disease (Evans et al., 1989; Jorm et al., 1987; Rocca et al., 1986).”
Whole brain quantitative T2 MRI across multiple scanners with dual echo FSE: Applications to AD, MCI, and normal aging
Bauer, C. M., Jara, H. J., & Killiany, R. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.04.255 · Cited by 47
“It is themost common formof dementia and is quickly becoming a global crisis, affecting approximately 10% of individuals over age 65 and nearly 50% of individuals over 85 years of age (Evans et al., 1989).”
Cognitive impairment and associated risk factors among aged community members
Yen, Y., Yang, M., Shih, C., & Lung, F. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1131 · Cited by 47
“The prevalence of cognitive impairment increases with age, and is approximately 5–10% among persons aged 65 years or older and as high as 20–47% in those older than 85 years (Heckler, 1985; Huppert, 1986; Evans et al., 1989).”
Physicians' Perspectives on Caring for Cognitively Impaired Elders
Adams, W. L., McIlvain, H. E., Geske, J. A., & Porter, J. L. (2005) · The Gerontologist · doi:10.1093/geront/45.2.231 · Cited by 47
Inner‐City Older Blacks Have High Levels of Functional Disability
Miller, D. K., Carter, M. E., Miller, J. P., Fornoff, J., Bentley, J. A., Boyd, S. D., Rogers, J. H., Cox, M., Morley, J. E., Lui, L., et al. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb01365.x · Cited by 47
Musical experience and dementia. Hypothesis
Grant, M. D., & Brody, J. A. (2004) · Aging Clinical and Experimental Research · doi:10.1007/bf03324571 · Cited by 46
“Dementia is a common illness among older individuals, the prevalence of probable AD reaching 10% (1).”
Marked Increase in Alzheimer's Disease Identified in Medicare Claims Records Between 1991 and 1999
Taylor, D. H., Sloan, F. A., & Doraiswamy, P. M. (2004) · The Journals of Gerontology Series A · doi:10.1093/gerona/59.7.m762 · Cited by 46
Timing of Disease Progression by Quantitative EEG in Alzheimer’s Patients
Nobili, F. M., Copello, F., Vitali, P., et al. (1999) · Journal of Clinical Neurophysiology · doi:10.1097/00004691-199911000-00008 · Cited by 46
DIFFERENTIAL DIAGNOSIS OF DEMENTIA
Folstein, M. F. (1997) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70392-0 · Cited by 46
Region-specific effects on brain metabolites of hypoxia and hyperoxia overlaid on cerebral ischemia in young and old rats: a quantitative proton magnetic resonance spectroscopy study
Macrì, M. A., d’Alessandro, N., Giulio, C. D., Iorio, P. D., Luzio, S. D., Giuliani, P., Esposito, E., & Pokorski, M. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-14 · Cited by 45
“Moreover, aging is the most important risk factor for neurodegenerative disorders, such as Alzheimer and Parkinson’s disease [16,17].”
Background
Hippocampal Function in Healthy Carriers of theCLUAlzheimer's Disease Risk Variant
Erk, S., Meyer‐Lindenberg, A., von Boberfeld, C. O., Esslinger, C., Schnell, K., Kirsch, P., Mattheisen, M., Mühleisen, T. W., Cichon, S., Witt, S. H., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4960-11.2011 · Cited by 46
“(Gatz et al., 2006) and affects nearly 10% of individuals at the age of 65 years and almost 50% of individuals who reach their nineties (Evans et al., 1989).”
Background
Who will Make Health Care Decisions for Me when I can't?
High, D. M. (1990) · Journal of Aging and Health · doi:10.1177/089826439000200301 · Cited by 45
Protective effects of berry polyphenols against age-related cognitive impairment
Bensalem, J., Dal‐Pan, A., Gillard, E., Calon, F., & Pallet, V. (2015) · Nutrition and Aging · doi:10.3233/nua-150051 · Cited by 46
APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy
Tsuboi, Y., Josephs, K. A., Cookson, N., & Dickson, D. W. (2003) · Neurology · doi:10.1212/01.wnl.0000044340.37138.a9 · Cited by 45
Accuracy of the Clock Drawing Test for Detecting Dementia in a Multicultural Sample of Elderly Australian Patients
Storey, J. E., Rowland, J. T. J., Basic, D., & Conforti, D. A. (2002) · International Psychogeriatrics · doi:10.1017/s1041610202008463 · Cited by 45
A Mathematical Model of Alzheimer's Disease and the Apoe Gene
Macdonald, A. S., & Pritchard, D. (2000) · Astin Bulletin · doi:10.2143/ast.30.1.504627 · Cited by 44
Greater habitual moderate-to-vigorous physical activity is associated with better executive function and higher prefrontal oxygenation in older adults
O'Brien, M. W., Kimmerly, D. S., & Mekari, S. (2021) · GeroScience · doi:10.1007/s11357-021-00391-5 · Cited by 44
Enhancement of Proxy Appointment for Older Persons: Physician Counselling in the Ambulatory Setting
Meier, D. E., Gold, G., Mertz, K., et al. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb05635.x · Cited by 44
Factor Analysis and Preliminary Validation of the Mini-Mental State Examination from a Longitudinal Perspective
Tinklenberg, J. R., Brooks, J. O., Tanke, E. D., et al. (1990) · International Psychogeriatrics · doi:10.1017/s1041610290000382 · Cited by 44
Rapidly Progressive Dementia
Day, G. S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001089 · Cited by 47
Coexistence of narcolepsy and Alzheimer's disease
Scammell, T. E., Matheson, J. K., Honda, M., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.12.008 · Cited by 43
“lence of 33%, similar to that of the general population (Evans et al., 1989; Hebert et al., 2003).”
Background
Burden of disease due to dementia in the elderly population of Korea: present and future
Park, J., Eum, J.-H., Bold, B., & Cheong, H. (2013) · BMC Public Health · doi:10.1186/1471-2458-13-293 · Cited by 42
The validity of the Hamilton and Montgomery-�sberg depression rating scales as screening and diagnostic tools for depression in Parkinson's disease
Leentjens, A. F. G., Verhey, F. R. J., Lousberg, R. L., Spitsbergen, H., & Wilmink, F. W. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200007)15:7 · Cited by 280
Vaccines for Alzheimer??s Disease
Janus, C. (2003) · CNS Drugs · doi:10.2165/00023210-200317070-00001 · Cited by 42
A Study of Delusions in a Large Cohort of Alzheimer's Disease Patients
Rockwell, E., Jackson, E., Vilke, G. M., & Jeste, D. V. (1994) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199405000-00009 · Cited by 45
Diagnostic approaches to Alzheimer’s disease
Boss, M. A. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00044-2 · Cited by 42
Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer’s disease (AD) risk
Raman, S., Brookhouser, N., & Brafman, D. A. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104788 · Cited by 41
Association of periodontitis and oral microbiomes with Alzheimer’s disease: A narrative systematic review
Mao, S., Huang, C.-P., Lan, H., Lau, H.-G., Chiang, C., & Chen, Y. (2022) · Journal of Dental Sciences · doi:10.1016/j.jds.2022.07.001 · Cited by 43
Preventing Cognitive Decline
Nolan, K. A., & Blass, J. P. (1992) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30495-6 · Cited by 42
Association of leisure-time physical activity with cognition by apolipoprotein-E genotype in persons aged 60 years and over: the National Health and Nutrition Examination Survey (NHANES-III)
Obisesan, T. O., Umar, U., Plauvoi, & Gillum (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s26794 · Cited by 41
Behavioral observations and quality of life among persons with dementia in 10 assisted living facilities
Kuhn, D., Kasayka, R. E., & Lechner, C. (2002) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/153331750201700508 · Cited by 42
Dementia and Assisted Living
Hyde, J., Pérez, R., & Forester, B. (2007) · The Gerontologist · doi:10.1093/geront/47.supplement_1.51 · Cited by 42
Statin therapy in the treatment of Alzheimer disease: what is the rationale?
DeKosky, S. T. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.09.006 · Cited by 43
Coenzyme Q10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen‐glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore
Li, G., Zou, L., Cao, C., & Yang, E. S. (2005) · BioFactors · doi:10.1002/biof.5520250111 · Cited by 41
“The mechanisms of neuronal injury and neuronal death overlap in both diseases [9,21,34].”
Prevalence and incidence of dementia among 75–80-year-old community-dwelling elderly in different districts of Antwerp, Belgium: The Antwerp Cognition (ANCOG) Study
Deyn, P. P. D., Goeman, J., Vervaet, A. M., Dourcy-Belle-Rose, B., Dam, D. V., & Geerts, E. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2011.07.030 · Cited by 41
COST: Cognitive State Test, a brief screening battery for Alzheimer disease in illiterate and literate patients
Yıldız, G. B., Işık, A. T., Ur, E., Aydemir, E., Ertas, C., Çebi, M., Soysal, P., Gürsoy, E. B., Kolukısa, M., Kocaman, G., et al. (2012) · International Psychogeriatrics · doi:10.1017/s1041610212001780 · Cited by 41
“(Evans et al., 1989; Corrada et al., 2010).”
Prevention of Alzheimer's disease
Szekely, C. A., Breitner, J. C. S., & Zandi, P. P. (2007) · International Review of Psychiatry · doi:10.1080/09540260701797944 · Cited by 41
“The rates of AD in those aged 85 and older maybe as high as 50% (Evans et al., 1989).”
Background
Estimating the Prevalence of Dementia in Elderly People: A Comparison of the Canadian Study of Health and Aging and National Population Health Survey Approaches
Thomas, V. S., Darvesh, S., MacKnight, C., & Rockwood, K. J. (2001) · International Psychogeriatrics · doi:10.1017/s1041610202008116 · Cited by 41
“does not cross a clinical threshold, but which is nevertheless important (Evans et al., 1989).”
Background
The PREMAP Study: Prevalence and risk factors of dementia and clinically diagnosed Alzheimer's disease in Provence, France
Obadia, Y., Rotily, M., Degrand-Guillaud, A., Guélain, J., Ceccaldi, M. P., Severo, C., Poncet, M., & Alpérovitch, A. (1997) · European Journal of Epidemiology · doi:10.1023/a:1007300305507 · Cited by 41
Geriatric Ideology: The Myth of the Myth of Senility
Goodwin, J. S. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb03607.x · Cited by 43
Screening for Cognitive Impairment and Dementia in the Elderly
Patterson, C. J. S., & Gass, D. A. (2001) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100001190 · Cited by 40
Neuronal gene expression profiling: uncovering the molecular biology of neurodegenerative disease
Mufson, E. J., Counts, S., Che, S., & Ginsberg, S. D. (2006) · Progress in brain research · doi:10.1016/s0079-6123(06)58010-0 · Cited by 40
Principles of Nonpharmacological Management: Caring for People With Alzheimer's Disease Using a Conceptual Model
Hall, G. R., Gerdner, L. A., Zwygart-Stauffacher, M., & Buckwalter, K. C. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950701-13 · Cited by 40
Linking Brain Imaging and Genomics in the Study of Alzheimer's Disease and Aging
Reiman, E. M. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1379.011 · Cited by 39
Molecular Biology and Transgenetics of Prion Diseases
Prusiner, S. B., & Lipton, H. L. (1991) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409239109086789 · Cited by 40
Alzheimer's disease risk factors as related to cerebral blood flow
Crawford, J. G. (1996) · Medical Hypotheses · doi:10.1016/s0306-9877(96)90189-9 · Cited by 40
EXPRESSIONS OF INDIVIDUALITY IN COGNITIVELY IMPAIRED ELDERS Need for Individual Assessment and Care
Burgener, S. C., Shimer, R., & MurelI, L. (1993) · Journal of Gerontological Nursing · doi:10.3928/0098-9134-19930401-05 · Cited by 40
Treatment of Alzheimer’s disease in the long-term-care setting
Smith, D. A. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070622 · Cited by 41
Cardiovascular Damage in Alzheimer Disease: Autopsy Findings From the Bryan ADRC
Corder, E. H., Ervin, J. F., Lockhart, E. L., Szymanski, M. H., Schmechel, D. E., & Hulette, C. M. (2005) · BioMed Research International · doi:10.1155/jbb.2005.189 · Cited by 37
“Population studies suggest that 47% of persons over age 85 are affected [1, 2, 3].”
Background
Dementia and Cognitive Impairment in the Oldest Old: A Comparison of Two Rating Methods
Johansson, B. E. A., & Zarit, S. H. (1991) · International Psychogeriatrics · doi:10.1017/s1041610291000492 · Cited by 39
“One recent report (Evans et al., 1989) suggested that prevalence of dementia of the Alzheimer type may be as high as 47% over age 85.”
Background
Membrane protein alterations in rodent erythrocytes and synaptosomes due to aging and hyperoxia
Hensley, K., Howard, B. J., Carney, J. M., et al. (1995) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/0925-4439(95)00043-4 · Cited by 39
Clinical Diagnosis and Course of Alzheimer's Disease
Morris, J. C., & Rubin, E. H. (1991) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30304-6 · Cited by 39
Energy, oxidative damage, and Alzheimer's disease: Clues to the underlying puzzle
Beal, M. F. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90198-8 · Cited by 38
Age as Risk Factor for Sporadic Dementia of the Alzheimer Type?
HOYER, S. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb56833.x · Cited by 38
Regional Cerebral Blood Flow Abnormalities in Nondemented Patients With Memory Impairment
Tanaka, M., Fukuyama, H., Yamauchi, H., Narita, M., Nabatame, H., Yokode, M., Fujimoto, N., Kita, T., & Murakami, M. (2002) · Journal of Neuroimaging · doi:10.1111/j.1552-6569.2002.tb00106.x · Cited by 38
Cost of Alzheimer's disease in a developing country setting
Zencir, M., Kuzu, N., Beşer, N. G., Ergin, A., Çatak, B., & Şahiner, T. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1332 · Cited by 39
“The prevalence of dementia in persons age 65 and older has been estimated to be between 2% and 10% in the US and between 3.3% and 6.0% in European populations (Pfeffer et al., 1987; Evans et al., 1989; Copeland et al., 1992; Fratiglioni et al., 1992).”
BackgroundInfluential
Treatment Strategies for the Behavioral Symptoms of Alzheimer's Disease: Focus on Early Pharmacologic Intervention
Beier, M. T. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.399 · Cited by 38
“5 million Americans in 2000,(2) and is most prevalent in the elderly, occurring in 3% of the population aged 65–74 years, 19% of the population aged 75–84 years, and in almost 50% of seniors aged 85 years or older.(3) Alzheimer’s disease is particularly common among nursing home residents, with more than half of those…”
Background
Enhanced antidepressant efficacy of σ1 receptor agonists in rats after chronic intracerebroventricular infusion of β-amyloid-(1–40) protein
Urani, A., Romieu, P., Roman, F. J., Yamada, K., Noda, Y., Kamei, H., Tran, H. M., Nagai, T., Nabeshima, T., & Maurice, T. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.018 · Cited by 38
Predictors of Healthy Brain Aging
McNeal, M. G., Zareparsi, S., Camicioli, R. M., Dame, A., Howieson, D. B., Quinn, J. F., Ball, M. J., Kaye, J. A., & Payami, H. (2001) · The Journals of Gerontology Series A · doi:10.1093/gerona/56.7.b294 · Cited by 38
The Epidemiology of Selected Mental Disorders in Later Life
Anthony, J. C., & Aboraya, A. (1992) · Elsevier eBooks · doi:10.1016/b978-0-12-101277-9.50006-1 · Cited by 38
Impact of body mass index on neuronal fiber bundle lengths among healthy older adults
Bolzenius, J. D., Laidlaw, D. H., Cabeen, R. P., Conturo, T. E., McMichael, A. R., Lane, E., Heaps, J. M., Salminen, L. E., Baker, L. M., Gunstad, J., et al. (2013) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9230-7 · Cited by 37
“Another reason for this discrepancy might be that the cohort in the current study was relatively young, especially in the context of cognitive impairment and dementia (Evans et al. 1989).”
Background
Cerium Oxide Nanoparticles for the Treatment of Neurological Oxidative Stress Diseases
Estevez, A. Y., & Erlichman, J. S. (2011) · ACS symposium series · doi:10.1021/bk-2011-1083.ch009 · Cited by 37
Differential Diagnosis of Alzheimer’s Disease
Morris, J. C. (1994) · Clinics in Geriatric Medicine · doi:10.1016/s0749-0690(18)30345-8 · Cited by 38
Dementing disorders in north Italy: Prevalence study in Vescovato, Cremona Province
Ferini‐Strambi, L., Marcone, A., Garancini, P., et al. (1997) · European Journal of Epidemiology · doi:10.1023/a:1007340727385 · Cited by 37

Authors: Evans, D. A.
Corresponding author: Evans, Denis A.
ORCID: Evans, Denis A.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1989-11-10
Volume: 262
Issue: 18
Pages: 2551
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1989.03430180093036
OpenAlex: W2129678592
Cited by: 1,226
References: 0
Citations by year: 2026: 6 · 2025: 11 · 2024: 13 · 2023: 15 · 2022: 9 · 2021: 20 · 2020: 22 · 2019: 17 · 2018: 20 · 2017: 18 · 2016: 28 · 2015: 23 · 2014: 17 · 2013: 32 · 2012: 25
FWCI: 44.57
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Funders: National Institute on Aging (N01-AG02107, N01‐AG‐1‐2106, AG 06789)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Aging, Health, and Disability
Keywords: Alzheimer's disease, prevalence, older adults, dementia, age-related cognitive decline, community-dwelling older adults, cognitive impairment, age differences in prevalence, public health impact

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prevalence of Alzheimer's Disease in a Community Population of Older Persons: Higher Than Previously Reported

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks